
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More